# Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

> **NCT01200589** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 438 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** Ofatumumab
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Ofatumumab
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT01200589
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10-11
- **Primary completion:** 2016-12-19
- **Final completion:** 2016-12-19
- **Target enrollment:** 438 (ACTUAL)
- **Why stopped:** The study stopped due to futility.
- **Last updated:** 2018-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01200589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01200589, "Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01200589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*